From the desk of J. D. Faccinetti, co-founder – We are big fans; collaboration works. Our experience and research suggest that when collaboration between organizations is strong, learning improves, and outcomes…
By J D Faccinetti, co-founder – In a three-day conference packed with thousands of scientists, endocrinologists, industry, and researchers, ENDO 2023 Conference presented a comprehensive review of the latest in pituitary disease advances, treatment, management, developments,
Acroline™ is a series of four brochures created by Pfizer in collaboration with an international panel of people with acromegaly, acromegaly support groups, and health psychologists. This series of supportive guides and tools are designed to help keep your life on track and live well with acromegaly.
We take advantage of Acromegaly Day, coming up on November 1, to highlight resources from industry partners. The Pfizer Patient Affairs Liaisons (PALs) connect patients and caregivers affected by rare conditions with programs and information. PALs work with
This study is available free. Just click on this link to download it. As a way of background, this is the second Phase 3 study for ISTURISA (osilodrostat). The first phase 3 study, LINC 3,
We caught up with Sheila a few weeks ago at the Acromegaly Community Conference near San Francisco. We had a captivating chat about Mycapssa (oral octreotide) and about Amryt’s start in Dublin, Ireland, just six years ago, its philosophy, brand, and plans.
Amryt Pharma announced positive results for the MPOWERED phase 3 trial for Mycapssa® oral octreotide for acromegaly patients, in a recent press release. The trial paves the way for the approval of Mycapssa® by the EMA.
The Corcept Therapeutics “Grace Study”, designed to evaluate the benefits and side effects of a new medication for people with endogenous Cushing’s syndrome, continues full steam ahead. The company recently announced the availability of new
Kudos to Pfizer’s new series on patient support. The first one features critical advice on emotional and mental help support! The materials provide valuable content given the importance of mental health issues to acromegaly patients.
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly
Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of an octreotide subcutaneous depot to treat acromegaly. This new treatment offers